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Ebola Virus Exploits a Monocyte Differentiation Program To Promote
Its Entry
Osvaldo Martinez,a Joshua C. Johnson,b Anna Honko,b Benjamin Yen,a Reed S. Shabman,a Lisa E. Hensley,c Gene G. Olinger,b
Christopher F. Baslera
Icahn School of Medicine at Mount Sinai, New York, New York, USAa; U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USAb; Medical
Countermeasures Initiative, FDA OCS/OCET, Silver Spring, Maryland, USAc
Antigen-presenting cells (APCs) are critical targets of Ebola virus (EBOV) infection in vivo. However, the susceptibility of mono-
cytes to infection is controversial. Studies indicate productive monocyte infection, and yet monocytes are also reported to be
resistant to EBOVGP-mediated entry. In contrast, monocyte-derived macrophages and dendritic cells are permissive for both
EBOV entry and replication. Here, freshly isolated monocytes are demonstrated to indeed be refractory to EBOV entry. How-
ever, EBOV binds monocytes, and delayed entry occurs during monocyte differentiation. Cultured monocytes spontaneously
downregulate the expression of viral entry restriction factors such as interferon-inducible transmembrane proteins, while up-
regulating the expression of critical EBOV entry factors cathepsin B and NPC1. Moreover, these processes are accelerated by
EBOV infection. Finally, ectopic expression of NPC1 is sufficient to rescue entry into an undifferentiated, normally nonpermis-
sive monocytic cell line. These results define the molecular basis for infection of APCs and suggest means to limit APC infection.
Zaire Ebola virus (EBOV) is an emerging zoonotic pathogenthat has caused outbreaks of viral hemorrhagic fever in hu-
mans with fatality rates approaching 90% (1). EBOV tropism to-
ward antigen-presenting cells (APCs) is thought to play an impor-
tant role in viral pathogenesis, contributing to the establishment
of infection and to the development of hemorrhagic fever (2).
EBOV productively infects APCs, including monocytes, macro-
phages, and dendritic cells (DCs), in vitro (3–9), and tissue sec-
tions from EBOV-infected humans and nonhuman primates con-
tain APCs positive for EBOV antigen/nucleic acid, demonstrating
APC infection in vivo (10–16). Although APCs serve as sites of
virus amplification, their infection also deregulates APC function
(2, 17, 18). This deregulation may contribute to the development
of an ineffective antiviral immune response, as well as an intense
and deregulated inflammatory response (4, 19).
Although monocytes, the most abundant blood-borne APCs,
likely contribute to EBOV pathogenesis, an apparent discrepancy
exists in our understanding of monocyte infection by EBOV (18).
Specifically, although EBOV productively infects human blood-
derived monocytes (4, 20), several other studies demonstrate lim-
ited or restricted EBOV GP-mediated entry into monocytes
(21–23).
EBOV entry, which includes attachment and penetration into
the target cell cytoplasm, is mediated by the surface glycoprotein
(GP) (24). GP likely mediates viral attachment through the recep-
tor-binding domain (RBD) located at its N terminus (25–28).
Subsequent viral uptake likely occurs via macropinocytosis (29–
32). A number of cell surface molecules, including C-type lectins,
have been identified as attachment or entry factors (33–38). How-
ever, none of these factors appears to function as an essential cell
surface receptor. Additional host factors have also been implicated
as regulating entry, including components of the homotypic fu-
sion and vacuole protein-sorting (HOPS) multisubunit tethering
complex, the cysteine proteases cathepsin L and cathepsin B and
signaling molecules, including acid sphingomyelinase and phos-
phoinositide-3 kinase (25, 26, 39–44). Recently, Niemann-Pick
C1 (NPC1), an endosomal protein involved in cholesterol trans-
port and storage, was identified as an essential EBOV entry recep-
tor (39, 45, 46). Negatively acting entry restriction factors have
also been identified, including the interferon-inducible trans-
membrane proteins (IFITMs) (47, 48).
Here we sought to define the basis of EBOV tropism toward
monocytes, macrophages, and DCs. The data indicate that undif-
ferentiated monocytes are indeed refractory to EBOV entry,
whereas macrophages and DCs are fully permissive. However,
EBOV can associate with undifferentiated monocytes and can
complete the entry process as the cells spontaneously differentiate
into macrophages or DCs. This results in substantially delayed
entry kinetics and less robust cytokine responses of monocytes
relative to differentiated macrophages or DCs. Profiling an array
of genes previously implicated in EBOV entry demonstrates that
during monocyte differentiation essential entry factors NPC1 and
cathepsin B increase, while the restriction factors IFITM1, -2, and
-3 decrease. Furthermore, although monocyte infection with
EBOV accelerates the rate of IFITM downregulation, the kinetics
of upregulation of cathepsin B and NPC1 expression remain
largely unchanged. Lastly, overexpression of NPC1 in THP-1
monocytes, which are nonpermissive for EBOV GP-mediated en-
try unless differentiated into macrophage-like cells, partially res-
cued EBOV GP-mediated entry.
MATERIALS AND METHODS
Cell culture, vectors, and plasmids.HEK293T (293T) cells were cultured
in Dulbecco modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 1% L-glutamine. The plasmids used in trans-
fections included (i) pcDNA BLA-VP40, which expresses a -lactamase-
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Zaire EBOV VP40 chimera (49, 50), (ii) pCAGGS GFP-VP40, which ex-
presses a VP40-GFP chimera (51), (iii) pcDNA EBGP, which expresses
wild-type Zaire EBOV strain Mayinga GP, (iv) pcDNA EBGPF88A (50,
52, 53), (v) pcDNA EBGPF159A (53), or (vi) pcDNA VSVG, which ex-
presses vesicular stomatitis virus glycoprotein (VSV G). NPC1 was ex-
pressed using the pBABE expression retroviral vector kindly provided by
Kartik Chandran (Albert Einstein College of Medicine).
Isolation and culture of humanmonocytes,macrophages, andDCs.
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll den-
sity gradient centrifugation (Histopaque; Sigma-Aldrich, St. Louis, MO)
from the buffy coats of healthy human donors (New York Blood Center).
CD14 monocytes were purified using anti-human CD14 antibody-la-
beled magnetic beads and iron-based LS columns (Miltenyi Biotec, Au-
burn, CA) and used immediately or further differentiated into macro-
phages or DCs. Stains of isolated monocytes typically showed 90%
positivity for CD14 staining. Monocytes were plated (0.7 106 to 1 106
cells/ml) in DC medium (RPMI [Invitrogen, Carlsbad, CA] supple-
mented with 100 U of penicillin/ml, 10 g of streptomycin/ml, 55 M
-mercaptoethanol, and 4% human serum AB [GemCell; Gemini Bio-
Products, West Sacramento, CA]) supplemented with either 500 U of
human granulocyte-macrophage colony-stimulating factor (GM-CSF;
Peprotech, Rocky Hill, NJ)/ml, 500 U of human interleukin-4 (IL-4; Pe-
protech)/ml to differentiate into DCs (54), or 20 to 50 ng of macrophage
colony-stimulating factor (M-CSF; Peprotech)/ml to differentiate into
macrophages. By day 5, immature DCs expressed surface CD11c, CD1c,
and HLA-DR (major histocompatibility complex [MHC] II) and low/
negative levels of CD14, whereas macrophages retained high levels of
CD14 and were HLA-DR positive (55, 56) and were permissive for EBOV
entry and infection (50).
VLP production and purification. For virus-like particle (VLP) pro-
duction, 293T cells were cotransfected with a combination of two plas-
mids using Lipofectamine 2000 (DNA/Lipofectamine 2000 ratio of 1:1):
either pcDNA BLA-VP40 or pCAGGS GFP-VP40, and either pcDNA ex-
pressing EBGP or VSV G at a ratio of 3:2 for VP40 to envelope glycopro-
tein. The VLPs were harvested at 3 days posttransfection; the 293T cell
spent supernatant was layered over 10 ml of 20% sucrose in NTE buffer
(100 mM NaCl, 20 mM Tris-hydrochloride [pH 7.5], and 1 mM EDTA
[EDTA]), and VLPs were pelleted at 25,000 rpm in an SW-28 rotor
(80,000 g) for 2 h at 4°C. The VLPs were then gently washed without
resuspension with 25 ml of cold NTE or phosphate-buffered saline (PBS)
and centrifuged again. The VLPs were finally resuspended in a total of 150
l of NTE and stored on ice at 4°C.
Flow cytometry. Flow cytometry was performed using an LSR II flow
cytometer equipped with a violet laser (BD Bioscience). The data were
analyzed using FlowJo software (Tree Star, Ashland, OR).
Mouse macrophages and dendritic cells. C57/BL6 mice were sacri-
ficed in order to obtain peritoneal macrophages (large CD11b cells) or
bone marrow cells according to standard techniques. In order to induce
monocyte differentiation into dendritic cells (DCs) or macrophages,
mouse bone-marrow cells grown in DMEM plus 10% FBS were supple-
mented with mouse GM-CSF (50 ng/ml; Peprotech) or M-CSF (20 ng/ml;
Peprotech), respectively. All animal procedures were performed in accor-
dance with Institutional Animal Care and Use Committee (IACUC)
guidelines and have been approved by the IACUC of Mount Sinai School
of Medicine.
Determining EBOV infectious titers. EBOV titers were determined
using an agarose plaque assay. Briefly, VeroE6 cells were plated in six-well
plates to 90 to 100% confluence. Fivefold dilutions of stock virus were
prepared (101 to 106.5). Medium samples were removed from the six-
well plates, and 200 l of inoculum for each dilution was added to each
well of the plate (six replicates), rocked, and allowed to incubate for 1 h at
37°C and 5% CO2, with rocking every 15 min to prevent the cell layer from
drying. At the end of the absorption period, each well was overlaid with 2
ml of a 1 agarose overlay (1% agarose mixed with 2 Eagle modified
essential medium [EMEM; Gibco], 2Anti-Anti [Gibco], 2GlutaMAX
[Gibco], and 10% fetal calf serum [FCS; Gibco] to yield a final overlay of
0.5% agarose [SeaKem ME agarose; Lonza], 1 EMEM, 1 Anti-Anti,
1GlutaMAX, and 5% FCS). The agarose was allowed to solidify, and the
plates were returned to an incubator. On day 9 after the primary overlay,
a secondary overlay of the primary overlay mixture plus 4% neutral red
(Gibco) was added, the samples were allowed to solidify, and the cells were
again returned to the incubator for an additional night. Plaques were
counted the following day, and the titers were determined.
Entry assays. Entry assays were performed as outlined in a previous
study (50). Different VLP preparations were used such that equivalent
levels of -lactamase activity were present for the entry assays. VLPs were
mixed with target cells and centrifuged (“spinoculated”) at 1,850 rpm for
45 min at 4°C before incubation at 37°C in 2% RPMI medium for the
indicated times. Target cells were then loaded with fluorescent CCF2-AM
substrate for 1 h at room temperature. An LSR II (BD Bioscience) flow
cytometer equipped with a violet laser was used to excite the CCF2-AM
substrate, and events (cells) were assayed for green and blue fluorescence
after sorting for live cells. Live cells were sorted using side-scatter and
forward-scatter properties (low side scatter and high forward scatter [data
not shown]) and for their ability to retain the CCF2-AM substrate (cells
that fluoresce green) since at least a subset of dead cells are permeable and
therefore leaky. Cells fluorescing blue compared to the control (for exam-
ple, mock control [results not shown]) were scored as entry positive.
EBOV infections. All EBOV infections were performed at the U.S.
Army Medical Research Institute of Infectious Diseases at biosafety level 4.
Monocytes, macrophages, and DCs were infected with EBOVGFP (50) or
EBOV (Kikwit 1995) at the indicated multiplicities of infection (MOIs)
for 1 to 2 h with rocking. When infecting human cells with the EBOVGFP,
we used MOIs of 5 and 10 because this consistently results in a significant
level of infection (20%). After infection, cells were washed three times
with PBS, resuspended, and plated in triplicate. To enumerate the per-
centages of cells infected by EBOVGFP, the cells were gently scraped off the
plates on at 2 and 3 days postinfection and analyzed by flow cytometry
after gating out dead cells using side-scatter and forward-scatter proper-
ties (side scatter low, forward scatter high). To identify secreted cytokines
induced after EBOVGFP infection, day 3 spent supernatants from infected
and noninfected control cells were analyzed as described below. To deter-
mine the gene expression (mRNA) levels, total RNA was first harvested
using Tri-Reagent, which was added to each well containing (infected)
cells, and then pipetted to make sure the cells were dissociated and lysed,
and the cell lysate was further processed as outlined below.
RNA isolation and cDNA synthesis. RNA was extracted from the
aqueous phase of the Tri-Reagent (Sigma-Aldrich) samples using an
RNeasy micro kit (Qiagen), including a DNase step as recommended by
the manufacturer. cDNA was generated from isolated mRNA using a Su-
perscript III first-strand synthesis kit (Invitrogen) using an oligo(dT)
primer as outlined by the manufacturer.
Quantitative reverse transcription-PCR (RT-PCR). Primers were
designed by using online real-time PCR primer design software and se-
lecting intron-spanning primers (Roche Applied Science [http://www
.rocheappliedscience.com/sis/rtpcr/upl/index.jsp?iduplct_000000]). Since
IFITM genes show high sequence identity, rather than just relying on the
PCR primer design software, the IFITM primers were modified to span
nucleotides that allowed for specific IFITM type amplification. EBOV NP
primers were previously used to assay for EBOV NP expression (57).
Table 1 provides the nucleotide sequences (5= to 3=) for the forward and
reverse primers used, respectively, for each human and EBOV gene.
Relative gene expression was determined using the iQ SYBR green
Supermix (Bio-Rad) according to the manufacturer’s instructions. The
PCR temperature profile was 95°C for 10 min, followed by 40 cycles of
95°C for 10 s and 60°C for 60 s. All of the reactions were performed in
triplicate, and standard error bars were added to graphs (see Fig. 7). CXF
Manager software (Bio-Rad) was used to analyze the relative mRNA ex-
pression levels by the change in threshold cycle (	CT) method using the
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene to normalize
Martinez et al.
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the results. To determine the NP mRNA levels in EBOV-infected mono-
cytes and DCs, a standard curve generated by using an NP expression
plasmid as a template was used to calculate the relative copy numbers of
NP mRNA from equal numbers of cells.
Fluorescence microscopy. Monocytes were infected with green fluo-
rescent protein (GFP)-tagged VLPs pseudotyped with EBGP as described
above except that the cells were spinoculated at 1,850 rpm for 45 min at
4°C onto coverslips. Monocyte VLPs were gently washed twice with PBS
supplemented with calcium and magnesium (PBS-CM) before incuba-
tion at 37°C in 2% RPMI medium for 0, 1.5, and 4 h. The cells were fixed
in 4% paraformaldehyde in PBS-CM and cell surface stained with fluo-
rescently labeled wheat germ agglutinin (Invitrogen). Coverslips were
washed in PBS-CM twice and once in water and then mounted in antifade
reagent (ProLong Gold; Invitrogen) before they were viewed using a con-
focal Leica SP5 DMI microscope. At least five different random fields were
used to determine the number of fluorescent VLPs that were taken up by
monocytes.
Measurement of cytokines. Cytokine measurements were conducted
in triplicate using a human cytokine 30-plex panel (Invitrogen) in accor-
dance with the manufacturer’s instructions. The data were acquired using
a LuminexFlexMAP 3D system (Bio-Rad) and exported to Bio-Rad Bio-
plex Manager 6.0 for data analysis. Standard curves were optimized by
using a software algorithm based on a five-parameter logarithmic curve
fit.
RESULTS
EBOV GP-mediated entry into monocytes is restricted. Several
published studies report the productive replication of EBOV in
primary human monocytes (4, 20), while others report that EBOV
GP pseudotyped viruses are unable to enter monocytes (21–23).
To begin to address this apparent discrepancy, we used an estab-
lished virus-like particle (VLP) entry assay in which VLPs pseu-
dotyped with either EBOV GP or control VSV glycoprotein (VSV-
G), either of which can mediate entry (50), contain -lactamase
fused to VP40 (BLA-VP40). Purified VLPs are incubated with a
target cell for a defined period of time after which entry is assayed.
Successful entry results in the delivery of -lactamase into the
target cell cytoplasm where it cleaves a preloaded cytosolic fluo-
rescent substrate (Fig. 1A). Once cleaved by -lactamase the sub-
strate-loaded cells fluoresce blue, while uncleaved substrate-
loaded cells fluoresce green (50, 58).
We first tested whether EBOV VLP entry into freshly isolated
undifferentiated monocytes was restricted compared to macro-
phages and DCs that were differentiated from M-CSF or GM-
CSFIL-4 cytokine-treated monocytes, respectively (54, 59–61).
VLPs were normalized for total-lactamase activity from purified
VLP preparations and were used to infect both human (Fig. 1B, D,
and E) and mouse (Fig. 1C) monocytes and macrophages. EBOV
GP-mediated entry was restricted in human (Fig. 1B) and mouse
(Fig. 1C) monocytes. In contrast, equivalent levels of VLPs en-
tered human (Fig. 1B and D) and mouse peritoneal (Fig. 1B) mac-
rophages. Although EBOV GP-mediated entry into monocytes
was restricted (consistently 10% [data not shown]), control
VSV G-mediated entry into human monocytes was efficient (less
so in mouse monocytes), demonstrating that the BLA-VP40 assay
can detect entry into human (Fig. 1B) and mouse (Fig. 1C) mono-
cytes. Assays testing entry restriction into monocytes compared to
DCs were repeated three times and gave results similar to those
shown in Fig. 1B and C. Since macrophages can be differentiated
from monocytes, these data suggest that entry permissiveness is
associated with a differentiated phenotype.
Efficient EBOV entry into differentiatedmonocytes. We also
found that entry into macrophages differentiated from monocytes
by M-CSF treatment was not significantly altered or restricted if
we also included IL-4, transforming growth factor  (TGF-), or
gamma interferon (IFN-
)— cytokines that regulate the expres-
sion of proteins, such as DC-SIGN, implicated in EBOV entry
(Fig. 1D and data not shown) (62–64). Similarly, entry into hu-
man blood monocyte-derived DCs differentiated from monocytes
by GM-CSF treatment (Fig. 1E) or mouse bone marrow-derived
DCs (not shown) was not significantly affected by IL-4, TGF-, or
IFN-
 treatment.
Kinetics of EBOV entry into differentiating monocytes.
Next, we determined at what point differentiating monocytes be-
TABLE 1 Primersused for quantitative RT-PCR
Entry factor
Forward and reverse primer sequences
(5=–3=)
IFITM1 CAACACCCTCTTCTTGAACTGG and
GCCGAATACCAGTAACAGGATG
IFITM2 GTTCAACACCCTCTTCATGAACA and
GACGACCAACACTGGGATGAT
IFITM3 CAACACCCTCTTCATGAACC and
CCTAGACTTCACGGAGTAGG
VPS33A GATCCGAGATAAGAACTTCAACG and
GATCTCCCCCACGGTCTTAG
VPS11 TCGAATCTTCCCTGCTATTCC and
AACACTGCCATCTGTGAAACC
VPS18 TTGTCGTCTCCAGCAATCAG and
CCTTGCCCAAGTCAATGC
VPS41 GAATTTTTGGAGAGTGATTATGAGG and
CGAACTGCTTGAACTATGACTGA
CTSB CTGTGGCAGCATGTGTGG and
CCTTTTCTTGTCCAGAAGTTCC
BLOC1S1 CGCCTCCTAAAAGAACACCA and
TAGCCTCTCGCCTCCTCTTT
GNPTAB TGAAGGAACTACAGCAGGTCAG and
TGTGTTTTTCCCAAGGATTTCT
MGL TACACCTGGATGGGCCTCAG and
TGTTCCATCCACCCACTTCC
DC-SIGN AGGCTCTGATTTCACGTCCC and
TGGGGACCTTGGACACTG
NPC1 GGTCCGCCTGTGTACTTTGT and
GGCTTCACCCAGTCGAAATA
LSECTIN ATTCTGAGTATCCTATTGTCCAAGG and
CTGCTTCGAGGCGTTTGT
DTK CTACCTCATTGGCGGGAAC and
ACTCCAGCACTGGTACATGAGA
MER ATTGGAGACAGGACCAAAGC and
GGGCAATATCCACCATGAAC
AXL CGTAACCTCCACCTGGTCTC and
TCCCATCGTCTGACAGCA
ITGB1 AATGAATGCCAAATGGGACACGGG and
TTCAGTGTTGTGGGATTTGCACGG
ITGB2 AAACAACATCCAGCCCATCTTCGC and
TGGACCACATTGCTGGAGT
TIM4 TGTGGAAAACGAGTGATTCTGT and
TTGTTCTGCTCAGGAACTGC
GAPDH CCATGTTCGTCATGGGTGTG and
GGTGCTAAGCAGTTGGTGGTG
L SIGN GCAGATACATGGCCACAAGA and
GGACACTTGGACAAGGATGG
EBOV NP 2034f-2106r CAGTGCGCCACTCACGGACA and
TGGTGTCAGCATGCGAGGGC
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come permissive for entry. Monocytes are typically differentiated
into immature DCs by incubation with GM-CSF plus IL-4 (54) for
5 to 7 days (50, 51, 55, 56). Therefore, we treated monocytes with
these cytokines for periods of 0, 18, 48, 72, 96, and 120 h before
testing for entry (Fig. 2A). As seen above (Fig. 1B), VSV G-medi-
ated entry into monocytes was highly efficient and did not require
differentiation-inducing cytokine treatment (Fig. 2B). On the
other hand, increased EBOV GP-mediated entry efficiency was
associated with increased duration of cytokine exposure. At 18 h
after cytokine treatment, 10% of the monocytes permitted en-
try, and only by 48 h was substantial entry into differentiating
monocytes detected (Fig. 2B). This experiment was repeated twice
with similar results.
EBOV infection ofmonocytes is delayed compared toDCs.A
recombinant EBOV expressing GFP (EBOVGFP [50]) was used to
test infection efficiency in monocytes and DCs. Using EBOVGFP at
MOIs of 5 and 10, monocytes and DCs were incubated with virus
for 2 h, washed, and incubated at 37°C. Few cells exhibited GFP
fluorescence by 24 h postinfection (data not shown). At 48 h
postinfection, there was an 3-fold difference in the number of
GFP monocytes and DCs (Fig. 2C), but this difference was no
longer apparent by 72 h postinfection (Fig. 2D) when the percent-
age of infected cells was comparable. The difference in the per-
centages of GFP cells indicates that undifferentiated monocytes
are permissive for EBOV infection, but the kinetics of replication
is slower in monocytes compared to DCs. The 72-h time point
from this experiment was repeated, confirming the reproducibil-
ity of these results.
Cultured monocytes become permissive for EBOV entry in
the absence of supplemental cytokines. Freshly plated and cul-
tured ex vivo monocytes slowly and spontaneously differentiate
(65–67). Therefore, we hypothesized that monocytes become per-
FIG 1 EBOV entry into monocytes is restricted. (A) Schematic representation of the entry assay protocol. -Lactamase-VP40 (BLA-VP40) containing VLPs
pseudotyped with either EBOV GP or VSV G is incubated with APCs for 3.5 h. Penetration into the cytoplasm is detected using a cytosolic substrate that fluoresces
blue once cleaved by BLA. Mock and purified EBOV GP VLPs and VSV G VLPs were used in entry assays using human (B) and mouse (C) monocytes,
macrophages, and human monocytes previously cultured for 5 days in the presence of M-CSF, M-CSF IL-4, M-CSF  TGF- (TGF-b), M-CSF  IFN-

(IFN-g) (D) and GM-CSF, GM-CSF IL-4, GM-CSF TGF- (TGF-b), GM-CSF IFN-
 (IFN-g) (E).
Martinez et al.
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missive for EBOV entry as they differentiate. We tested the kinet-
ics of EBOV entry when EBOV VLPs were added to plated mono-
cytes and cultured for up to 48 h in media not supplemented with
cytokines. In the experiments described above (Fig. 1A), VLPs
were incubated with target cells for 3.5 h before testing for cyto-
plasmic penetration. In this experiment (Fig. 3A), VLPs were
added to monocytes or DCs, gently washed, and the VLP target
cell mixture cultured for up to 2 days. At 2, 4, 6, 12, 24, and 48 h
after the addition of VLPs, monocytes and DCs were tested for
entry (Fig. 3B). We observed significant entry into DCs by 2 h after
VLP incubation, but significant entry into monocytes did not oc-
cur until the 12-h time point. In both cases, the percentage of
entry-positive cells reached a plateau at 24 h after VLP treat-
ment; however, monocytes never achieved the same level of infec-
tion as the DCs. This suggests that entry into monocytes was not
only delayed but that entry into undifferentiated monocytes is less
efficient than entry into fully differentiated DCs. This experiment
has been repeated with similar results.
Since significant entry into monocytes occurred after 24 h of
culture, we tested whether there was a significant difference in the
levels of the cell surface differentiation and adhesion markers
CD1c, CD14, CD11b, CD11c, ICAM-1, integrin 2, CD44,
MHC1, or MHC2 expressed between freshly isolated monocytes
and monocytes cultured for 24 h (Fig. 3C). Control DC cells, but
not monocytes, expressed significant cell surface levels of DC
marker CD1c, whereas the monocytes expressed higher levels of
CD14. However, there were no significant differences in the ex-
pression levels on freshly isolated monocytes compared to mono-
cytes cultured for 24 h of any of the markers tested, including
ICAM-1 and CD44 (data not shown and Fig. 3C).
Because primary monocytes spontaneously differentiate in
culture, it is difficult to determine whether differentiation is re-
quired for the delayed EBOV VLP entry. As an alternative, the
human monocyte-like cell line THP-1 was used in experiments to
address the role of differentiation in EBOV infection of mono-
cytes. This cell line is commonly used as an experimental model
for human monocytes, but these cells do not spontaneously dif-
ferentiate in culture. However, THP-1 cells can be induced to
differentiate by the addition of phorbol myristate acetate (PMA)
(68). This results in an adherent macrophage-like phenotype and
renders the cells permissive for EBOV GP-mediated entry (22).
We therefore tested for entry into THP-1 cells treated or not with
PMA (Fig. 4A). As with primary human monocytes, the undiffer-
entiated THP-1 cells were permissive for entry by VSV G, but not
by EBOV GP VLPs, whereas the differentiated THP1s allowed
entry (Fig. 4B). We again tested for the expression of CD1c, CD14,
CD11b, CD11c, ICAM-1, integrin 2, CD44, MHC1, or MHC2
on untreated and PMA-treated THP-1. Of all the markers tested,
only expression of ICAM-1, previously shown to be upregulated
on monocytes cultured for several days (69), was significantly up-
regulated on PMA-treated THP-1 cells (Fig. 4C). The combina-
tion of significant ICAM-1 expression and adherence (data not
FIG 2 EBOV entry and infection occurs during monocyte differentiation. A schematic representation of the experimental protocol used to test entry after
induction of monocyte differentiation is shown in panel A. (A and B) Freshly isolated blood monocytes were cultured in the presence of GM-CSFIL-4 for 0, 18,
48, 72, 96, and 120 h, harvested and tested for entry using mock, EBOV GP, EBOV GP F88A (entry mutant), or VSV G VLPs. (C and D) EBOVGFP was used to
infect monocytes and DCs at an MOI of 5 and 10. EBOV titers were determined on VeroE6 cells. Cells were harvested at day 2 (C) and day 3 (D) postinfection
and subjected to flow cytometry to determine the percentages of cells expressing GFP (EBOV infection).
EBOV Infects Monocytes during Differentiation
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FIG 3 Delayed EBOV entry into monocytes compared to DCs. (A) Schematic representation of a modified entry protocol used. Instead of incubating VLPs with target
host cells for 3.5 h (as in Fig. 1A), target cells and VLPs were incubated together for 2, 4, 6, 12, 24, and 48 h. The cells were then harvested and tested for VLP entry. (B)
Mock (ctl) and purified EBOV GP VLPs were incubated with freshly isolated monocytes and DCs for 2, 4, 6, 12, 24, and 48 h before testing for penetration into the
cytoplasm. Shown is the percentage of entry positive cells. (C) Freshly isolated monocytes, 24-h-cultured monocytes and differentiated DCs were stained with antibodies
against CD1c, CD14, ICAM-1, and CD44 and assayed by flow cytometry for cell surface expression (red line) compared to background staining (blue line).
3806 jvi.asm.org Journal of Virology
shown) suggests that the THP-1 cells have differentiated into a
macrophage-like cell. Since incubating blood monocytes with
VLPs for 24 h was sufficient time to allow significant EBOV GP-
mediated VLP entry (Fig. 3B), we tested whether a 24-h incuba-
tion with VLPs, in the absence of differentiation stimuli, would
rescue EBOV GP-mediated entry into THP-1 cells and included
primary monocytes as a positive control (Fig. 4D and E). As pre-
viously seen (Fig. 3B), VSV G VLPs entered THP-1 cells, whereas
the increased VLP incubation time of 24 h did not rescue EBOV
GP-mediated entry (Fig. 4E). However, the concomitant addition
of PMA and EBOV GP VLPs allowed EBOV GP-mediated entry.
VLPs pseudotyped with mutant GP-F159A were previously dem-
onstrated to be entry defective (53, 70). Therefore, GP-F159A
VLPs were used in entry assays to exclude the possibility that dif-
ferentiated monocytes (Fig. 4D) or THP-1 cells (Fig. 4E) might
indiscriminately take up any GP-expressing VLPs. The GP-F159A
VLPs showed no entry, demonstrating that neither the extended
time of VLP-cell incubation nor PMA treatment could render cells
permissive for this mutant. Taken together, the data demonstrate
that an increased VLP-cell incubation time in blood monocytes
but not in THP-1 cells eventually allows EBOV GP entry. THP-1
cells, which do not undergo spontaneous differentiation, allow
EBOV GP mediated entry only in the presence of PMA. Therefore,
entry into monocytes correlates with their differentiation.
EBOV transcription is delayed in monocytes compared to
DCs.Previous studies have shown that EBOV productively infects
monocytes. We sought to assess the entry kinetics of replication-
competent EBOV into undifferentiated monocytes, DCs, undif-
ferentiated THP-1 cells, and differentiated PMA-treated THP-1
cells. As a surrogate measure for viral entry, we profiled EBOV-
infected cells for the onset of viral transcription, using quantitative
reverse transcription-PCR (RT-PCR) (Fig. 5). Viral transcription
was assessed by measuring viral nucleoprotein (NP) mRNA levels
at 0, 6, 12, 24, and 48 h after EBOV infection at an MOI of 1.
FIG4 THP-1 cells become permissive for EBOV entry after PMA-mediated differentiation. (A) Schematic representation depicts the experimental protocol used
for experiment shown in panel B. (B) Purified Mock, EBOV GP, or VSV G VLPs were used to test entry permissiveness of THP-1 cells previously treated for 24
h with mock (no Tx) or PMA. Bar graphs show the percentages of entry positive THP-1 cells. (C) THP-1 cells treated or not with PMA for 24 h were stained with
antibodies against CD14, ICAM-1, and CD44 and assayed by flow cytometry for cell surface expression (red line) compared to background staining (blue line).
(D and E) Mock (no VLPs), EBOV GP F159A (an entry mutant), EBOV GP VLPs, and VSV G VLPs were incubated for 24 h with monocytes (D) and THP-1 cells
(E) in culture media supplemented with or without PMA before testing for penetration into the cytoplasm. Shown are the percentages of entry-positive cells.
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Consistent with the entry assay data, the appearance of EBOV NP
mRNA in monocytes was significantly delayed in comparison to
infected DCs (Fig. 5A and B), demonstrating that EBOV infection,
like EBOV VLP entry, is delayed in undifferentiated monocytes
compared to differentiated cells. Furthermore, NP expression was
apparent only in differentiated THP-1 cells and not in untreated
THP-1 cells, further supporting the view that differentiation is
required for early events in EBOV infection (Fig. 5C and D).
FIG 5 Kinetics of EBOV NP mRNA expression and EBOV GP VLPGFP uptake in monocytes. EBOV was used to infect—at an MOI of 1—DCs (A), monocytes
(B), and THP-1 cells (C) or THP-1 cells grown in medium supplemented with PMA (D). RNA was harvested from cells at 0, 3, 6, 12, 24, and 48 postinfection.
Poly(A)-derived cDNA was used as a template for quantitative RT-PCR analysis of EBOV nucleoprotein (NP) mRNA. The relative copy number is shown. (E)
EBOV GP VLPGFPs (green) were incubated with monocytes for 0, 1.5, and 4 h before fixation. Cell plasma membranes were stained (red) using wheat germ
agglutinin conjugated to a fluorochrome. Uptake of VLPs was analyzed using confocal microscope Leica SP5 DMI. (F) The percentages of EBOV GP VLPGFP were
scored as entering beyond the cell periphery (taken up) by monocytes if the VLP was inside the cell and not associated with the membrane. Totals of 39, 351, and
21 VLPs were scored at time points 0, 1.5, and 4 h, respectively.
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EBOV GP VLPGFP uptake in monocytes and DCs. To assess
the kinetics of EBOV GP VLP uptake into monocytes, we used fluo-
rescently tagged VLPs that were generated by coexpression of a chi-
meric GFP-VP40 protein and GP, leading to the formation of EBOV
GP VLPGFP (51). Monocytes were treated with equivalent amounts of
EBOV GP VLPGFPs, washed gently, and incubated for 0, 1.5, and 4 h
to allow the uptake of particles. Using confocal microscopy, VLP up-
take was assessed by visualizing the location of EBOV GP VLPGFPs
relative to the monocyte surface membrane. At 0 and 1.5 h postinfec-
tion, there was a clear association of fluorescently labeled cell mem-
branes (red) with fluorescent particles (green) (Fig. 5E). The VLPs
remained associated with the cell periphery until 4 h, when significant
numbers of the EBOV GP VLPGFPs had relocalized toward the inte-
rior of the monocytes (Fig. 4E). Specifically, at 0, 1.5, and 4 h postin-
fection, 0, 5, and 48% of EBOV GP VLPGFPs, respectively, were in the
cell interior regions of monocytes (Fig. 5F). These data, which have
been reproduced, demonstrate that EBOV GP VLPGFPs readily asso-
ciate with monocytes before entry occurs.
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Monocytes secrete limited levels of cytokines uponEBOV in-
fection. Cytokines produced by APCs are proposed to contribute
to EBOV pathogenesis (18). To test for the presence and levels of
several inflammatory cytokines, a multiplex assay was performed
on supernatants harvested 3 days after EBOV infection of mono-
cytes, macrophages, and DCs. A representative panel of secreted
cytokines (IL-12, IL-6, IL-8, MIP-1, MCP-1, RANTES, IFN-,
IP-10 and G-CSF) is presented in Fig. 6. Consistent with previous
studies, macrophages in general secreted comparably more in-
flammatory cytokines, but monocytes did secrete some inflamma-
tory cytokines, albeit at lower levels. Therefore, the differentiation
status and the type of APC affects both the efficiency/kinetics by
which EBOV infection is established and the inflammatory cyto-
kine response.
Expression levels of host factors critical for entry change
duringmonocyte differentiation andEBOV infection. Since sig-
nificant changes occur in the monocyte transcriptome during dif-
ferentiation (71), we tested the hypothesis that the levels of host
factors implicated in EBOV entry also change during monocyte
differentiation. The relative mRNA levels of select host entry fac-
tors (Table 2) were compared by quantitative RT-PCR between
undifferentiated monocytes and DCs. Of the mRNAs examined,
only the mRNA levels of cathepsin B, NPC1, IFITM1, and IFITM3
showed a 10-fold difference between monocytes and DCs.
Therefore, these specific mRNAs were chosen for further investi-
gation. The kinetics of mRNA expression of these host factors was
determined in cultured monocytes at 0, 3, 6, 12, 24, and 48 h after
plating. For comparison, the 120-h time point represents the rel-
ative mRNA levels in DCs. We also tested for the expression of
cathepsin B, NPC1, IFITM1, IFITM2, and IFITM3 mRNA levels
after monocyte infection with EBOV at an MOI of 1 (Fig. 7).
Comparison of undifferentiated monocytes with or without
EBOV infection revealed several striking findings. Although
IFITM entry restriction factor expression in cultured monocytes
dramatically decreases over time to the levels measured in DCs,
their expression initially increases during the first few hours after
plating. However, upon EBOV infection of monocytes, IFITM
expression immediately decreases. On the other hand, these same
infected cells demonstrate an upregulation of factors required for
entry, namely, NPC1 and cathepsin B. These data demonstrate
that the levels of host entry factors not only change during mono-
cyte differentiation, but EBOV infection also hastens the down-
regulation of entry restriction factors, while at the same time up-
regulating host factors that are required for entry.
Stable expressionofNPC1 fromTHP-1 cells partially rescues
EBOV entry. NPC1 is essential for EBOV infection, and there was
a 100-fold increase in NPC1 mRNA in DCs and macrophages
relative to monocytes (Fig. 8A). Western blotting for the levels of
NPC1 confirmed that the lower levels of mRNA correspond to
lower levels NPC1 protein expression in monocytes and higher
levels in DCs and macrophages (Fig. 8B). PMA differentiated
THP-1 cells also demonstrated higher levels of NPC1 protein
compared to their undifferentiated counterparts (Fig. 8B). To test
whether overexpressing NPC1 can rescue EBOV entry into undif-
ferentiated monocytic cells, THP-1 cells were stably transduced
with a retrovirus that expresses NPC1 and tested for EBOV GP
VLP entry. Overexpressing NPC1 partly rescued EBOV GP-medi-
ated entry (Fig. 8C), suggesting that low levels of NPC1 in mono-
cytes may determine, in part, their resistance to EBOV entry. This
experiment was repeated with similar results.
DISCUSSION
This study addresses seemingly contradictory observations that
monocytes are productively infected by EBOV but are nonpermis-
sive for EBOV GP-mediated entry (4, 20–23). Our initial studies,
wherein VLPs were incubated with undifferentiated or differenti-
ated target cells for 3.5 h (Fig. 1A), indicated that in the presence of
GM-CSFIL-4 (a standard protocol used to generate monocyte-
derived DCs), monocytes become permissive for entry by 48 h
after cytokine addition (Fig. 2A and B). On the other hand, if VLPs
were incubated for longer periods of time with cultured mono-
cytes, which spontaneously differentiate, substantial entry was de-
tected as early as 24 h post-VLP addition (Fig. 3B), although over-
all entry efficiency was consistently lower compared to DCs
(Fig. 3B). Studies with infectious EBOV, where we used NP
mRNA expression as a surrogate marker for entry (Fig. 5), support
this conclusion. These data suggest that monocytes are not incom-
petent for EBOV entry. Rather, entry is substantially delayed and
somewhat less efficient compared to DCs.
Primary monocytes spontaneously differentiate in culture.
Therefore, it is problematic to determine whether or not the delay
in entry requires the differentiation process. We therefore turned
to THP-1 cells, because these cells do not spontaneously differen-
tiate in culture, exhibit a strict resistance to entry as monocytes,
and become permissive following differentiation overnight with
PMA (Fig. 4B) (22). In these cells, prolonged incubation with
EBOV VLPs, in the absence of PMA did not lead to successful
entry. However, if prolonged incubation occurred with the coad-
dition of PMA, then THP-1 cells became entry positive by 24 h
TABLE 2 RelativemRNA levels of EBOV entry factors expressed by
monocytes and DCs
Entry factor Relative monocyte/hDC expressiona
Located at the cell surface
TIM-4 ND in monocytes
MER Similar
DTK Monocytes DCs
AXL Monocytes DCs
ITGB1 Similar
ITGB2 Similar
hMGL Similar
LSECTin ND
L-SIGN ND
DC-SIGN Similar
Located intracellularly
NPC1 Monocytes DCs*
VPS33A Similar
VPS11 Similar
VPS18 Similar
VPS41 Monocytes DCs
BLOC1S1 Similar
GNPTAB Monocytes DCs
Cat B Monocytes DCs*
IFITM1 Monocytes DCs*
IFITM2 Monocytes DCs
IFITM3 Monocytes DCs*
a The relative levels of EBOV entry factors were assayed for in freshly isolated
monocytes, as well as in DCs, and normalized to the levels of GAPDH. It is indicated,
for each gene, was whether the gene was expressed at a higher () or lower () level in
monocytes than in DCs. ND, not detected. *, A10-fold difference in mRNA levels.
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postinfection (Fig. 4E). Although we cannot fully exclude the pos-
sibility that entry requirements differ in THP-1 cells compared to
primary monocytes, these results suggested that differentiation is
a requirement for EBOV entry into monocytes.
Significant changes occur in the monocyte transcriptome dur-
ing differentiation (71), and this leads to altered expression of
select cell surface markers. Although no significant differences
were seen in the expression levels of such cell surface markers
when comparing freshly isolated monocytes and 24-h-cultured
monocytes, which are entry permissive (Fig. 3C), monocyte dif-
ferentiation and entry permissiveness did correlate with a decrease
in mRNA levels for entry restriction factors and an upregulation of
factors critical for EBOV entry, all of which occurred within hours
of monocyte culturing. Therefore, it is likely that monocytes be-
come permissive for entry before the differentiation process is
complete. Among the entry-relevant factors that change, IFITM1,
IFTIM2, and IFITM3 are among a family of IFN-inducible pro-
teins that when overexpressed restrict the entry of a variety of
viruses, including EBOV (47, 48, 72–75). We observed a dramatic
downregulation of the mRNA for each of these proteins during
FIG 7 mRNA levels of factors that regulate EBOV entry in plated monocytes with or without EBOV infection. Freshly isolated blood monocytes were plated or
infected with EBOV at an MOI of 1 before plating. RNA from infected and noninfected monocytes was harvested at 0, 3, 6, 12, 24, and 48 postinfection.
Poly(A)-derived cDNA was used as a template to amplify the levels of IFITM1, IFITM2, IFITM3, cathepsin B, and NPC1. The final time point (120 h) represents
the mRNA levels of that particular gene in what are considered to be differentiated, monocyte-derived DCs. The mRNA levels of each gene were normalized to
GAPDH. Each point represents a separate sample evaluated in triplicate. See also Table 2.
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the differentiation process, and this downregulation was acceler-
ated in EBOV-infected monocytes. Conversely, essential entry
factors cathepsin B and NPC1 are dramatically upregulated dur-
ing monocyte differentiation. In THP-1s, the patterns of NPC1
expression mirror what was seen in primary monocyte to macro-
phage or DC differentiation, and the expression of NPC1 via a
retroviral vector was sufficient to partially rescue entry into undif-
ferentiated THP-1 cells (Fig. 8). Whether NPC1 facilitates entry
directly, by acting as a receptor, or by some indirect mechanism
remains to be determined. Nonetheless, these data point to NPC1
upregulation as a critical determinant of entry into APCs.
Whether coexpression of other entry factors (e.g., cathepsin B) or
simultaneous knockdown of restriction factors (IFITMs) would
further enhance entry remains to be determined. In addition to
their role in EBOV entry, it will be of interest to determine how the
regulation of these factors generally affects monocyte and macro-
phage function.
Our microscopy studies indicate that VLPs attach to undiffer-
entiated monocytes at some frequency and that the VLPs can re-
main associated with the cells for at least several hours. However,
by the 4-h time point when the -lactamase-based entry assay
does not detect significant entry (Fig. 3) and NP mRNA remains
undetectable in EBOV-infected monocytes (Fig. 5), a significant
percentage of the particles had moved to an intracellular location
(Fig. 5). It remains to be determined whether the inward migra-
tion of VLPs at 4 h postinfection represents a pathway that leads to
productive entry. However, the data suggest that monocytes are
capable of supporting a certain level of viral attachment and that
VLPs remain monocyte-associated as these cells undergo differ-
entiation and become fully permissive for entry.
Previous studies implicated cell adherence versus nonadher-
ence as a determinant of EBOV entry into THP-1 and 293 cells
(22). Because differentiation of primary monocytes is intertwined
with the acquisition of adherence, we cannot exclude the possibil-
ity that the modulation of entry factors is a direct consequence of
adherence. Comparison of the ability of nonadherent and adher-
ent cells, including monocytes and macrophages, to bind to a re-
combinant EBOV GP receptor binding domain (RBD)-Fc protein
also indicated that adherence correlates with the translocation of
an RBD binding activity from an intracellular compartment to the
cell surface (21). Although our studies did demonstrate stable as-
sociation of VLPs with freshly isolated, nonadherent primary
monocytes, these studies do not directly address the presence of an
RBD binding factor on monocytes versus macrophages.
There are multiple potential consequences for the delayed en-
try of EBOV into monocytes. Monocytes are blood-borne phago-
cytic mononuclear cells (76) that can capture and present antigen.
Under inflammatory conditions, monocytes can also enter tissues
in order to differentiate into macrophages or DCs (77, 78). The
persistence of EBOV GP VLPs associated with monocytes suggests
the possibility that EBOV can hijack monocytes and potentially
“hide” from the host immune response within monocytes, using
migrating monocytes as a vehicle for dissemination. In this model,
completion of the entry process and onset of viral replication
might only occur after the monocytes enter tissue and differenti-
ate. In addition, we show that EBOV-infected monocyte cultures
secrete limited levels of cytokines (Fig. 6). Further studies are re-
quired to determine whether the lack of robust secretion of a sub-
set of cytokines is related to the delayed kinetics of viral entry.
EBOV infection appears to accelerate the transcriptional regu-
lation of entry-relevant host factors compared to uninfected,
plated monocytes (Fig. 7). EBOV can trigger signaling in macro-
phages within 1 h postinfection (79) and EBOV VLPs, which lack
viral replication machinery can also activate macrophages as well
as DCs. Furthermore, several of these studies have shown that
EBOV VLPs stimulate APCs in a GP-dependent manner, illustrat-
ing a central role for the attachment protein in an entry process
that itself induces signaling (3, 51, 80). Therefore, it will be of
interest to identify the signals responsible for EBOV-induced
transcriptional regulation. By defining the pathways required for
EBOV to differentiate and enter monocytes, it may be possible to
devise strategies that will impair the infection of APCs, potentially
blunt their cytokine and other responses and thereby influence
EBOV pathogenesis.
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